Qyuns Therapeutics Snares ￥10M in Series B+ Round

According to 36Kr.com, Jiangsu Quan Xin Biomedical Co., Ltd. ("Qyuns Therapeutics") has closed its Series B+ round led by Lucky Source Funds, with participation from Jiayin Fund. Previously, Qyuns Therapeutics has completed a ￥100M Series B financing led by Hongtai Aplus, with participation from Triwise Capital and Hefu Ruitai. 

Founded in 2015 in China Medical City (Taizhou), Qyuns Therapeutics is a biopharmaceutical company focused on the development of high-quality antibody drugs for the treatment of autoimmune diseases. The company aims to improve patient access to advanced and affordable medicine through science and innovation.  In collaboration with domestic and international partners (Qyuns Therapeutics has signed a global strategic cooperation agreement with Seneca Biopharma of innovative monoclonal antibodies for the treatment of immune-related diseases), the company develops new antibodies in the "bio-similar" and "bio-better" categories.

The two co-founders of Qyuns Therapeutics possess over 20-year experience in developing therapeutic antibody drugs. The company has a team of highly-skilled talents with extensive experience across drug development, CMC, quality, and compliance.  

Qyuns Therapeutics has eight programs under research and development, covering indications included psoriasis, atopic dermatitis, rheumatoid arthritis, inflammatory bowel disease, asthma, etc. In addition, the company has two biosimilars to enter the phase III clinical trial, and its first innovative drug is about to enter phase II, with a number of pipelines that will enter the clinical stage or complete preclinical development by 2020.

Besides, the CDMO platform project jointly built by Qyuns Therapeutics and China Medical City for biological drugs has been fully launched, and 8 production lines will be built in the first phase. The platform is the key project of China Medical City, which can not only prepare for the mass production of Qyuns Therapeutics, but also serve other biopharmaceutical enterprises.

Lucky Source Funds is an equity investment firm focuses on biomedical health, with its business covering investment in angel, VC, PE, and industrial mergers and acquisitions. At present, the company mainly invests in the fields of innovation and high-end generic drugs, high-end medical equipment and related components, and medical services.